Omega-3 Fatty Acids for Neuropathic Pain: Case Series

Articles & Publications on BPI related sciences
Locked
User avatar
Christopher
Posts: 845
Joined: Wed Jun 18, 2003 10:09 pm
Injury Description, Date, extent, surgical intervention etc: Date of Injury: 12/15/02

Level of Injury:
-dominant side C5, C6, & C7 avulsed. C8 & T1 stretched & crushed

BPI Related Surgeries:
-2 Intercostal nerves grafted to Biceps muscle,
-Free-Gracilis muscle transfer to Biceps Region innervated with 2 Intercostal nerves grafts.
-2 Sural nerves harvested from both Calves for nerve grafting.
-Partial Ulnar nerve grafted to Long Triceps.
-Uninjured C7 Hemi-Contralateral cross-over to Deltoid muscle.
-Wrist flexor tendon transfer to middle, ring, & pinky finger extensors.

Surgical medical facility:
Brachial Plexus Clinic at The Mayo Clinic, Rochester MN
(all surgeries successful)

"Do what you can, with what you have, where you are."
~Theodore Roosevelt
Location: Los Angeles, California USA

Omega-3 Fatty Acids for Neuropathic Pain: Case Series

Post by Christopher »

http://journals.lww.com/clinicalpain/Ab ... se.14.aspx
The Clinical Journal of Pain:
February 2010 - Volume 26 - Issue 2 - pp 168-172
doi: 10.1097/AJP.0b013e3181bb8533
Case Reports
Omega-3 Fatty Acids for Neuropathic Pain: Case Series
Ko, Gordon D. MD, CCFP (EM), FRCPC, FABPMR, FABPM; Nowacki, Nathaniel Benjamin BSc; Arseneau, Leigh ND; Eitel, Melanie RMA; Hum, Annie MD
Collapse Box
Abstract

Objective: The aim of this case series study was to investigate and report on patients with neuropathic pain who responded to treatment with omega-3 fatty acids.

Methods: Methods: Five patients with different underlying diagnoses including cervical radiculopathy, thoracic outlet syndrome, fibromyalgia, carpal tunnel syndrome, burn injury were treated with high oral doses of omega 3 fish oil (varying from 2400-7200 mg/day of EPA-DHA). Outcome measures were obtained pretreatment and posttreatment. These included validated surveys (short-form McGill Pain questionnaire, DN4 neuropathic pain scale, Pain Detect Questionnaire), objective clinical tools (Jamar grip strength, Lafayette dynamometry, tender point algometry) and EMG Nerve Conduction studies.

Results: These patients had clinically significant pain reduction, improved function as documented with both subjective and objective outcome measures up to as much as 19 months after treatment initiation. No serious adverse effects were reported.

Conclusions: This first-ever reported case series suggests that omega-3 fatty acids may be of benefit in the management of patients with neuropathic pain. Further investigations with randomized controlled trials in a more specific neuropathic pain population would be warranted.
Locked